Large-scale, granular biological datasets such as proteomic, metabolomic, and transcriptomic profiles are powering the current shift toward precision medicine.
Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Stanford researchers have patented protein stability regulation methods using destabilizing domains (DDs) optimized for use in humans. The ability to control specific protein abundance in cells is a powerful tool for gene therapy and investigating biological behavior.